Knight Therapeutics Inc. Company Profile | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Knight Therapeutics Inc.

Knight Therapeutics Inc.

Knight Therapeutics Inc.
Stock Exchange	Other OTC
EPS	$0.12
Market Cap	$818.9 M
Shares Outstanding	142.83 M
Public Float	-

Knight Therapeutics Inc.
Stock Exchange	Frankfurt Stock Exchange
EPS	-
Market Cap	-
Shares Outstanding	142.83 M
Public Float	-

Knight Therapeutics Inc.
Stock Exchange	Toronto Stock Exchange Prices
EPS	CAD0.16
Market Cap	CAD1.08 B
Shares Outstanding	142.81 M
Public Float	110.06 M

Profile

Address	3400, de Maisonneuve Boulevard West Montréal Québec H3Z 3B8 Canada
Employees	-
Website	http://www.gud-knight.com
Updated	07/08/2019
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Financials

Samira Sakhia

President, Chief Financial Officer & Director

Jonathan Ross Goodman

Chief Executive Officer & Director